Interpace Biosciences: CMS delays Genetic Testing LCD to April 24, 2025; Company re-evaluates restructuring plan

INTERPACE BIOSCIENCES, INC.

CMS directed Medicare contractors to delay implementation of LCD L39365 from Feb 23 to April 24, 2025.
Delay allows Trump administration to review clinical evidence for PancraGEN assay and assess patient impact.
Interpace will continue offering PancraGEN and re-evaluate its previously announced restructuring plan.
CEO Burnell stated the company is sustainable without PancraGEN but extension preserves jobs and patient access.
PancraGEN has been covered by Medicare for over 10 years, helped over 80,000 patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.